Board to consider Dividend
Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company is scheduled to be held on May 16, 2017, inter alia, to consider the Audited Standalone and Consolidated Financial Results of the Company for the year ended March 31, 2017 and dividend if any.Further, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the... Board Meeting On 16Th May 2017
Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, we wish to inform you that the Board Meeting of the Company is scheduled to be held on Tuesday, May 16, 2017 at the registered office of the Company at 5.00 p.m. to consider inter alia, the Audited Standalone and Consolidated Financial Results of the Company for the year ended 31st March, 2017 and dividend... Certificate Under Regulation 40(9) & (10) For The Half Year Ended 31St March, 2017
Certification under Clause 40 (9) of the Listing Regulations for the period 1st October, 2016 to 31st March, 2017. Shareholding for the Period Ended March 31, 2017
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here Compliance Certificate For The Period Ended 31St March, 2017
Certificate Under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half yearly ended on 31st March, 2017 Statement Of Investors Complaints For The Quarter Ended 31St March, 2017
Pursuant to Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), please find below a Statement containing redressal of investor's complaints for the quarter ended 31st March, 2017. Outcome of Board Meeting
Bliss GVS Pharma Ltd has informed BSE regarding Outcome of Board Meeting held on February 09, 2017. Standalone & Consolidated Financial Results, Limited Review Report for December 31, 2016
Bliss GVS Pharma Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Consolidated Financial Results for the period ended December 31, 20163. Standalone Limited Review for the period ended December 31, 20164. Consolidated Limited Review for the period ended December 31, 2016 Board Meeting Intimation for Results & Closure of Trading Window
Bliss GVS Pharma Ltd has informed BSE that the Board Meeting of the Company is scheduled to be held on February 09, 2017, inter alia, to consider the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2016.Further, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the Company,... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Bliss GVS Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.